Physician profile
Matthew E Bohm
NPI 1831345362
$239,367.60
in general payments reported to CMS, 2019-2025
18 companies · $144K in 2025
The $144K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $2,209 · 2021: $583 · 2022: $6,211 · 2023: $19K · 2024: $66K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $213K · Food and Beverage: $10K · Travel and Lodging: $5,403 · Consulting Fee: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $212,934.86 |
| Food and Beverage | $10,306.28 |
| Travel and Lodging | $5,402.59 |
| Consulting Fee | $1,150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $106,124.76 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $93,102.62 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $37,967.65 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $707.02 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gi Supply, INC. | $600.00 | 2020 | |
| Pfizer INC. | $190.37 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $151.66 | 2021-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $120.70 | 2024-2025 | Dupixent |
| Celgene Corporation | $115.00 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.96 | 2019-2025 | Xifaxan |
| Braintree Laboratories, INC. | $58.68 | 2024-2025 | Suflave, Sutab |
| Qol Medical, LLC | $37.28 | 2025 | Sucraid |
| Aimmune Therapeutics, INC. | $27.00 | 2023 | |
| Celltrion USA INC. | $23.74 | 2025 | Vegzelma |
| Boston Scientific Corporation | $22.26 | 2025 | Cre Pro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17.65 | 2024 | |
| Olympus America INC. | $14.25 | 2025 | Single Use Repositionable Clip |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bohm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.